Skip to main content

Month: June 2021

Driven By Stem CEO, Adam Berk, Provides Shareholder Update During Virtual Road Show on ChannelChek

BOCA RATON, FL, June 29, 2021 (GLOBE NEWSWIRE) — Stem Holdings, Inc. d/b/a Driven by Stem (OTCQX: STMH) (CSE: STEM) (the “Company” or “Stem“), the first multi-state, vertically integrated Farm-to-Home™ (F2H) cultivation and technology omnichannel cannabis company featuring a proprietary Delivery-as-a-Service (DaaS) marketplace platform, today announced the availability of its virtual road show presentation on ChannelChek, which can be accessed at www.drivenbystem.com, or https://www.channelchek.com/channelcast-detail/WET7Ezi6uh. During the presentation CEO, Adam Berk, provides shareholders with an update on its vertical integration Farm-to-Home™ strategy, as well as the Company’s organic and acquisitive growth plans. About Stem Holdings Stem Holdings is a leading omnichannel, vertically-integrated cannabis...

Continue reading

Flora Growth Establishes Long-Term Commitment to Environmental and Economic Sustainability

Flora Growth Corp. Commits to Sustainable and Eco-friendly Practices Throughout Diverse Brand Portfolio Supply Chains TORONTO, June 29, 2021 (GLOBE NEWSWIRE) — Flora Growth Corp. (NASDAQ: FLGC) (“Flora”, “Flora Growth”, or the “Company”), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to announce that its commitment to environmental sustainability will be represented across the Company’s value chain. Flora Growth’s sustainability initiatives will focus on the modern eco-conscious consumer looking for products made with cruelty-free, natural ingredients in sustainable, biodegradable packaging. “At Flora, we have made sustainability a pillar of our strategy. We are doing this because consumers are guiding us in this direction, because we’re committed to our planet and our people,” said...

Continue reading

Vision Marine Technologies Fast Tracks Commercialization of our E-Motion™ Electric Powertrain with Up to $1.72 Million (CAD) in Grants Secured from the Government of Quebec

Grants pave the way for Vision Marine to showcase its E-Motion™180 proprietary powertrain technology MONTREAL, June 29, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (NASAQ: VMAR) (“Vision Marine” or the “Company”), announced today that the government of Québec through Investissement Québec (IQ), an important catalyst for the Province of Quebec economic development, granted up to $1.72 million (CAD), in the form of a non-refundable contribution to fast track commercialization of the E-Motion™ 180. “I am honored and proud of what my team has been able to accomplish in such a short period of time. We have been able to demonstrate that our proprietary technology will be a disrupter within the industry. This grant will help to allow us to equip watercraft from major manufacturers to showcase E-Motion’s™ performance and range,”...

Continue reading

Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States

NATESTO® Coverage now Includes 85% of Commercial Lives TORONTO, June 29, 2021 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, effective July 1, 2021, an additional leading pharmacy benefit manager (PBM) in the United States has elected to make NATESTO® (testosterone nasal gel) a “Preferred Brand” on its National Preferred Drug List. “This new formulary placement is another key milestone in Acerus’ commercial efforts in the United States,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “We now have, without a doubt, best-in-class branded coverage, which we anticipate will lead to enhanced patient access and increased physician prescribing...

Continue reading

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has entered into a non-binding letter of intent (the “LOI”) to acquire BayMedica Inc. (“BayMedica”), a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable, and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer...

Continue reading

Builders FirstSource to Acquire WTS Paradigm, LLC, a Software Solutions and Services Provider for the Building Products Industry

Transaction accelerates annual billion dollar digital opportunity for Builders FirstSource and advances its strategy to invest in innovative digital solutions that help customers build more efficiently Paradigm’s technology will drive efficiencies and productivity in the building supply chain, enhancing Builders FirstSource’s portfolio of value-added products and services Enhanced digital solutions are expected to improve customer satisfaction and drive growth and operating efficiency for Builders FirstSource’s distribution business DALLAS, June 29, 2021 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (Nasdaq: BLDR) (“Builders FirstSource”), today announced that it has entered into a definitive agreement to acquire WTS Paradigm, LLC (“Paradigm”), a software solutions and services provider for the building products industry, in a...

Continue reading

Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors

Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. PHILADELPHIA, June 29, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors, effective upon the closing of the previously announced merger (the “Merger”) between Renovacor and Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”). The closing of the Merger is expected to occur in the third quarter of 2021. Upon the close of the Merger, Mr. Covino will also serve as the Chair of Renovacor’s...

Continue reading

FactSet Reports Solid Results for Third Quarter 2021

Record Quarterly Revenue Hits $400 Million NORWALK, Conn., June 29, 2021 (GLOBE NEWSWIRE) — FactSet (“FactSet” or the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, today announced results for its third quarter ended May 31, 2021. Third Quarter Fiscal 2021 HighlightsRevenue increased 6.8%, or $25.5 million, to $399.6 million compared with $374.1 million for the same period in fiscal 2020. The increase is primarily due to higher sales of analytics and content and technology solutions (CTS). Organic revenues grew 5.9% to $397.4 million during the third quarter of fiscal 2021 from the prior year period.Annual Subscription Value (ASV) plus professional services was $1.6 billion at May 31, 2021, compared with $1.5 billion...

Continue reading

Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)

Company announcement – No. 43/ 2021 Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)Company to present three posters, including two on glepaglutide for the treatment of Short Bowel Syndrome (SBS) Data demonstrate potential dosing benefits of glepaglutide for patients with SBSCopenhagen, DK and Boston, MA, U.S. June 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced it will present three posters at the upcoming 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA), which is being held both virtually and in Auckland, New Zealand June 30-July 2, 2021. The Company’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.